Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES F LOVELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1174629448
CMS profile
325880
Location
NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$454.03

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $454.03 20

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES F LOVELL

NPI 1174629448 · CMS profile ID 325880

Allopathic & Osteopathic Physicians / Internal Medicine

NORFOLK, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174629448?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174629448?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174629448?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHARLES F LOVELL, NPI 1174629448, CMS profile ID 325880, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1174629448?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $454.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $15.5012/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015841775 CMS
Amgen Inc. $19.5311/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020551785 CMS
AstraZeneca Pharmaceuticals LP $16.5510/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015913018 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.5810/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996475001 CMS
AstraZeneca Pharmaceuticals LP $101.6909/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011838769 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.8707/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996475005 CMS
AstraZeneca Pharmaceuticals LP $22.4907/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011264615 CMS
AstraZeneca Pharmaceuticals LP $14.4706/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015827995 CMS
Horizon Therapeutics plc $12.9806/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987039973 CMS
Horizon Therapeutics plc $17.8805/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987039971 CMS
Novartis Pharmaceuticals Corporation $18.8405/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991986447 CMS
Lilly USA, LLC $15.1105/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031312099 CMS
Novo Nordisk Inc $16.4605/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001041537 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.3505/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997130383 CMS
AstraZeneca Pharmaceuticals LP $20.3704/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015313883 CMS
Corcept Therapeutics $35.8704/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050825579 CMS
AstraZeneca Pharmaceuticals LP $13.3102/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015946811 CMS
Corcept Therapeutics $17.9402/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050825529 CMS
Lilly USA, LLC $13.1302/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031310479 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.1101/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997066017 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,516.90 64
PY2020 $2,823.11 39
PY2021 $2,590.74 45
PY2022 $737.64 35
PY2023 $454.03 20
PY2024 $2,529.63 39
PY2025 $681.28 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,318.22 41
PY2024 Principal investigator $226,779.68 27
PY2023 Principal investigator $241,422.11 79
PY2022 Principal investigator $283,192.02 266
PY2021 Principal investigator $197,651.91 425
PY2020 Principal investigator $248,697.42 325
PY2019 Recipient $12,988.10 1
PY2019 Principal investigator $359,002.06 260

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,421.90 12/03/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
IS354CS15 No dispute reported 06/30/2026 1246791017
Principal investigator 1 Eli Lilly and Company $2,648.00 12/02/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF MUVALAPLIN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE HAD A PRIOR ATHEROSCLEROTIC CARDIOVASCULAR EVENT OR ARE AT RISK FOR A FIRST ATHEROSCLEROTIC CARDIOVASCULAR EVENT – MOVE-LP(A) No dispute reported 06/30/2026 1187892896
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770821
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,536.59 12/01/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190300285
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 11/18/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998449
Principal investigator 1 Novartis Pharmaceuticals Corporation $50.57 11/15/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190300289
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 11/13/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815125
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770819
Principal investigator 1 ModernaTX, Inc. $806.76 10/22/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252956381
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 10/09/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815123
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,020.00 10/08/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
IS354CS9 No dispute reported 06/30/2026 1246788515
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,275.00 10/08/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
IS354CS9 No dispute reported 06/30/2026 1246788519
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,803.40 10/08/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
IS354CS9 No dispute reported 06/30/2026 1246788522
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770817
Principal investigator 1 AstraZeneca Pharmaceuticals LP $45,975.35 09/24/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185550038
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770811
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770813
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770815
Principal investigator 1 ModernaTX, Inc. $151.20 08/22/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252956383
Principal investigator 1 PFIZER INC. $1,616.08 08/05/2025 Non-covered Recipient Entity
York Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCEDAILY ORAL DANUGLIPRON IN ADULTS WITH OVERWEIGHT OR OBESITY No dispute reported 06/30/2026 1228765668
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770803
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770805
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770807
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
York Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770809
Principal investigator 1 ModernaTX, Inc. $85.20 07/23/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252956379
Principal investigator 1 PFIZER INC. $2,351.00 07/16/2025 Non-covered Recipient Entity
York Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCEDAILY ORAL DANUGLIPRON IN ADULTS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES No dispute reported 06/30/2026 1228764470
Principal investigator 1 Novo Nordisk AS $29.00 06/30/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1213745586
Principal investigator 1 ModernaTX, Inc. $1,100.88 06/18/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252956385
Principal investigator 1 Novo Nordisk AS $29.00 05/30/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1213737087
Principal investigator 1 Novo Nordisk AS $29.00 04/30/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1213831997
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,106.55 04/23/2025 Non-covered Recipient Entity
AVICENNA DM CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185550033
Principal investigator 1 Novo Nordisk AS $29.00 03/31/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1213719028
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,659.68 02/28/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Phase IIb Multicenter Randomised DoubleBlind Dose-inding Study to Evaluate the Efficacy Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria No dispute reported 06/30/2026 1185550035
Principal investigator 1 Novo Nordisk AS $29.00 02/28/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1213741142
Principal investigator 1 AstraZeneca Pharmaceuticals LP $139,047.08 02/21/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1185550027
Principal investigator 1 Novo Nordisk AS $29.00 01/31/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
NN9535-4801 No dispute reported 06/30/2026 1213717498
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,657.29 01/30/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190300287
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,963.44 01/29/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185550031
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,261.47 01/22/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 1185550029
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,675.03 01/15/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH, LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190300291
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $6,657.32 01/01/2025 Non-covered Recipient Entity
YORK CLINICAL RESEARCH LLC
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214124744